Literature DB >> 24830390

(G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.

Jun-Shiao Chou1, Chu-Yu Chen1, Ying-Ling Chen2, Yi-Hsin Weng3, Tu-Hsueh Yeh3, Chin-Song Lu4, Ya-Ming Chang5, Hung-Li Wang6.   

Abstract

Twelve- to sixteen-month-old (G2019S) LRRK2 transgenic mice prepared by us displayed progressive neuronal death of substantia nigra pars compacta (SNpc) dopaminergic cells. In the present study, we hypothesized that prior to a late-phase death of SNpc dopaminergic neurons, (G2019S) LRRK2 also causes an early-phase neuronal dysfunction of SNpc dopaminergic cells in the (G2019S) LRRK2 mouse. Eight to nine-month-old (G2019S) LRRK2 transgenic mice exhibited the symptom of hypoactivity in the absence of the degeneration of SNpc dopaminergic neurons or nigrostriatal dopaminergic terminals. Whole-cell current-clamp recordings of SNpc dopaminergic cells in brain slices demonstrated a significant decrease in spontaneous firing frequency of SNpc dopaminergic neurons of 8-month-old (G2019S) LRRK2 mice. Carbon fiber electrode amperometry recording using striatal slices showed that (G2019S) LRRK2 transgenic mice at the age of 8 to 9months display an impaired evoked dopamine release in the dorsolateral striatum. Normal nigrostriatal dopaminergic transmission is required for the induction of long-term synaptic plasticity expressed at corticostriatal glutamatergic synapses of striatal medium spiny neurons. Whole-cell voltage-clamp recordings showed that in contrast to medium spiny neurons of 8 to 9-month-old wild-type mice, high-frequency stimulation of corticostriatal afferents failed to induce long-term depression (LTD) of corticostriatal EPSCs in medium spiny neurons of (G2019S) LRRK2 mice at the same age. Our study provides the evidence that mutant (G2019S) LRRK2 causes early-phase dysfunctions of SNpc dopaminergic neurons, including a decrease in spontaneous firing rate and a reduction in evoked dopamine release, and impairment of corticostriatal LTD in the (G2019S) LRRK2 transgenic mouse.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (G2019S) LRRK2; (G2019S) LRRK2 transgenic mouse; Corticostriatal long-term depression; Corticostriatal long-term potentiation; Evoked dopamine release; SNpc dopaminergic neurons; Striatal medium spiny neurons

Mesh:

Substances:

Year:  2014        PMID: 24830390     DOI: 10.1016/j.nbd.2014.04.021

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  17 in total

Review 1.  Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?

Authors:  Yvette C Wong; Kelvin Luk; Kerry Purtell; Samuel Burke Nanni; A Jon Stoessl; Louis-Eric Trudeau; Zhenyu Yue; Dimitri Krainc; Wolfgang Oertel; Jose A Obeso; Laura A Volpicelli-Daley
Journal:  Mov Disord       Date:  2019-09-04       Impact factor: 10.338

2.  Age-related LRRK2 G2019S Mutation Impacts Microglial Dopaminergic Fiber Refinement and Synaptic Pruning Involved in Abnormal Behaviors.

Authors:  Qiuyang Zhang; Xiaojuan Cheng; Wei Wu; Siyu Yang; Hanlin You; Zucheng Ye; Nan Liu; Xiaochun Chen; Xiaodong Pan
Journal:  J Mol Neurosci       Date:  2021-08-19       Impact factor: 3.444

Review 3.  Physiological and pathological functions of LRRK2: implications from substrate proteins.

Authors:  Miho Araki; Genta Ito; Taisuke Tomita
Journal:  Neuronal Signal       Date:  2018-10-10

Review 4.  Spiny Projection Neuron Dynamics in Toxin and Transgenic Models of Parkinson's Disease.

Authors:  Yijuan Du; Steven M Graves
Journal:  Front Neural Circuits       Date:  2019-03-15       Impact factor: 3.492

5.  Leucine-rich repeat kinase-2 (LRRK2) modulates paraquat-induced inflammatory sickness and stress phenotype.

Authors:  Chris Rudyk; Zach Dwyer; Shawn Hayley
Journal:  J Neuroinflammation       Date:  2019-06-07       Impact factor: 8.322

6.  Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration.

Authors:  Chrystian J Alves; Rafael Dariolli; Frederico M Jorge; Matheus R Monteiro; Jessica R Maximino; Roberto S Martins; Bryan E Strauss; José E Krieger; Dagoberto Callegaro; Gerson Chadi
Journal:  Front Cell Neurosci       Date:  2015-08-04       Impact factor: 5.505

Review 7.  Centrality of Early Synaptopathy in Parkinson's Disease.

Authors:  Paola Imbriani; Tommaso Schirinzi; Maria Meringolo; Nicola B Mercuri; Antonio Pisani
Journal:  Front Neurol       Date:  2018-03-01       Impact factor: 4.003

8.  Validation of differentially expressed brain-enriched microRNAs in the plasma of PD patients.

Authors:  Stylianos Ravanidis; Anastasia Bougea; Nikolaos Papagiannakis; Christos Koros; Athina Maria Simitsi; Ioanna Pachi; Marianthi Breza; Leonidas Stefanis; Epaminondas Doxakis
Journal:  Ann Clin Transl Neurol       Date:  2020-08-29       Impact factor: 4.511

Review 9.  From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson's Disease: Lessons From LRRK2.

Authors:  Andrea Mancini; Petra Mazzocchetti; Miriam Sciaccaluga; Alfredo Megaro; Laura Bellingacci; Dayne A Beccano-Kelly; Massimiliano Di Filippo; Alessandro Tozzi; Paolo Calabresi
Journal:  Front Cell Neurosci       Date:  2020-07-28       Impact factor: 5.505

10.  The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.

Authors:  Eric S Sweet; Bernadette Saunier-Rebori; Zhenyu Yue; Robert D Blitzer
Journal:  J Neurosci       Date:  2015-08-12       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.